by Organ-on-chip are microfluidic cell culture chips that mimic the activities and physiological responses of human organs and organ systems. These devices are used in drug development and toxicity testing as alternatives to animal testing. They allow researchers to observe the complex interactions between various cell types in a living organ and the ability of potential therapeutics to impact those interactions.
The global Organ On A Chip Market is estimated to be valued at US$ 228.24 Mn in 2023 and is expected to exhibit a CAGR of 3.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The growing need of drug development is propelling the organ on a chip market. Traditional drug testing methods often fail in human trials since they do not accurately simulate complex human biology. Organ chips better mimic human physiology, disease progression, and responses to therapeutics which can significantly improve success rates in clinical trials by identifying toxic or inefficient drug candidates earlier. They allow testing of new therapeutics on living replicas of human organs like lung, liver, intestine etc in a more accurate and ethical way as compared to animal models. This is expected to drive increasing adoption of organ chips by pharmaceutical companies for early stage drug screening and development over the forecast period.
SWOT Analysis
Strength: Organ on chip technology enables testing of new drugs in a safe, ethical and cost effective manner without using animals. It can also model human disease conditions better than cell or tissue culture models.
Weakness: Developing functional multi organ chip systems that can accurately mimic human physiology and disease conditions is technically challenging. Long term culturing of organ chip systems is also difficult to achieve.
Opportunity: The technology has potential applications in personalized medicine, disease modeling, toxicity screening and fundamental biological research. It can reduce dependence on animal models for medical research.
Threats: Commercial success depends on demonstrating clear advantages over existing preclinical models. High development costs and regulatory hurdles for validating this novel approach may slow market adoption. Intellectual property litigation between companies is also a risk.
Key Takeaways
The Global Organ On A Chip Market Size is expected to witness high growth over the forecast period driven by technological advances and increased research funding. The global Organ On A Chip Market is estimated to be valued at US$ 228.24 Mn in 2023 and is expected to exhibit a CAGR of 3.1% over the forecast period 2023 to 2030.
North America currently dominates the market due to presence of major players and higher adoption of advanced preclinical research models. The Asia Pacific region is expected to grow at the fastest pace supported by increasing R&D expenditure and focus on developing alternatives to animal testing in countries like China, Japan and South Korea.
Key players operating in the organ on a chip market include Emulate, TissUse, Hesperos, CN Bio Innovations, Tara Biosystems and Nortis among others. These firms are focused on developing multi-organ systems capable of recapitulating key aspects of human physiology. Partnerships with pharmaceutical companies are also enabling drug development and safety testing applications of organ chips. Several startups in this field have also attracted funding from government agencies and venture capital investors who recognize the long term commercial potential.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile itÂ
